- Home
- AUST vs CTXR Comparison
AUST vs CTXR Comparison
Compare AUST & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- CTXR
- Stock Information
- Founded
- AUST 2020
- CTXR 2007
- Country
- AUST Canada
- CTXR United States
- Employees
- AUST N/A
- CTXR N/A
- Industry
- AUST
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- CTXR Health Care
- Exchange
- AUST Nasdaq
- CTXR Nasdaq
- Market Cap
- AUST 19.0M
- CTXR 18.7M
- IPO Year
- AUST 2022
- CTXR N/A
- Fundamental
- Price
- AUST $1.33
- CTXR $1.35
- Analyst Decision
- AUST
- CTXR Strong Buy
- Analyst Count
- AUST 0
- CTXR 3
- Target Price
- AUST N/A
- CTXR $53.00
- AVG Volume (30 Days)
- AUST 81.1K
- CTXR 351.2K
- Earning Date
- AUST 08-06-2025
- CTXR 08-12-2025
- Dividend Yield
- AUST N/A
- CTXR N/A
- EPS Growth
- AUST N/A
- CTXR N/A
- EPS
- AUST N/A
- CTXR N/A
- Revenue
- AUST N/A
- CTXR N/A
- Revenue This Year
- AUST N/A
- CTXR N/A
- Revenue Next Year
- AUST N/A
- CTXR $365.90
- P/E Ratio
- AUST N/A
- CTXR N/A
- Revenue Growth
- AUST N/A
- CTXR N/A
- 52 Week Low
- AUST $0.85
- CTXR $0.65
- 52 Week High
- AUST $3.19
- CTXR $17.00
- Technical
- Relative Strength Index (RSI)
- AUST 51.75
- CTXR 49.89
- Support Level
- AUST $1.25
- CTXR $1.18
- Resistance Level
- AUST $1.36
- CTXR $1.45
- Average True Range (ATR)
- AUST 0.06
- CTXR 0.10
- MACD
- AUST 0.01
- CTXR -0.00
- Stochastic Oscillator
- AUST 39.95
- CTXR 62.96
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.